Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in acute myeloid leukaemia

14-Dec-2012 - Norway

Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed.  The results found that treatment with the elacytarabine/idarubicin combination showed promising clinical activity with a complete remission (CR/CRi) rate of approximately 43% in patients who failed to respond to first-course treatment (20 of 46 evaluable patients). To date, 13 patients were deemed fit enough following treatment to be referred for stem cell transplantation, which represents a potential cure for these patients. The safety profile is consistent with this type of cytotoxic therapies.

The main objective of the 51-patient trial is to demonstrate that patients failing cytarabine can be rescued by elacytarabine.

Olav Hellebø, Clavis Pharma CEO, commented: "The results have shown that elacytarabine in combination with idarubicin elicits a therapeutic effect in a substantial proportion of early stage AML patients for whom first-course cytarabine treatment failed. This is very encouraging and highlights the potential of elacytarabine to offer a new treatment option to patients who may not respond to current standard cytarabine-containing therapies. We would like to thank the investigators and their patients for taking part in this study.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Clavis Pharma Announces Recruitment of Patients in Phase II Study comparing CP-4126 with gemcitabine in pancreatic cancer

Clavis Pharma announces encouraging interim results of Phase II trial with elacytarabine in combination with idarubicin in patients with AML - Biomarker analysis suggests hENT1 levels may identify patients for whom elacytarabine could be an effective treatment

Novartis to sell stake in consumer healthcare joint venture to GSK - Focussing on strategic priorities

1.5 million USD in new funding & new chairman of the board to iSentio AS

QIAGEN and Bayer HealthCare partner to develop companion diagnostics to guide treatment decisions for targeted cancer therapies

Novocure Announces Appointment of Wilco Groenhuysen as Chief Financial Officer

Clavis Pharma's CP-4126 Enters New Phase II Clinical Trial in Pancreatic Cancer Patients Refractory to 1st line Gemcitabine Therapy

Navamedic's glucosamine HCl product approved in 19 European countries for treatment of osteoarthritis

Bayer and Zydus Cadila sign Joint Venture Agreement to strengthen pharmaceutical business in India

Promising interim results of Phase II trial with elacytarabine in combination with idarubicin in patients with early stage acute myeloid leukaemia (AML)

Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer

The Netherlands Cancer Institute (NKI) and to-BBB to collaborate on brain delivery of anti-cancer drugs